Narazaciclib combined with letrozole is used to treat endometrioid endometrial cancer. Credit: Nephron / commons.wikimedia.org.

Onconova Therapeutics has dosed the first patient in its Phase I/IIa clinical trial of narazaciclib combined with letrozole to treat endometrial cancer.

The multicentre, open-label study will evaluate narazaciclib in combination with letrozole as a second or third-line treatment for patients with recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company intends to conduct the trial at the study’s principal investigator site, sites affiliated with MD Anderson Cancer Center, US Oncology Research sites, and NYU Langone Health.

The Phase I dose escalation portion of the trial will be initiated first followed by a Phase II expansion cohort.

Determining a recommended Phase II dose (RP2D) by evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of the combination is the primary objective of the Phase I portion.

Phase II expansion cohort will enrol over 30 patients and its primary objective is to evaluate the efficacy of the combination at the RP2D, as measured by 24-week progression-free survival.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, exploratory objective of the study is to record the estrogen/progesterone receptor status of participants.

Onconova president and CEO Steven Fruchtman said: “Our recurrent LGEEC programme provides an opportunity to establish narazaciclib as a best-in-class therapy in an indication where clinical proof-of-concept for its mechanism of action has been demonstrated.

“We, therefore, view the programme as a key avenue for value creation and look forward to our Phase I/IIa trial’s preliminary data readout expected later this year.”

A multi-kinase inhibitor, narazaciclib targets CDK 4, CDK 6, and other kinases which are important for cell proliferation and motility.